title: Hypoglycemic potency of novel trivalent chromium in hyperglycemic insulin-deficient rats.
abstract: Two sources of chromium III, "chromium 454" and "chromium picolinate," were tested in insulin-deficient Streptozocin-treated diabetic rats. This model was selected in order to evaluate the possibility of any hypoglycemic potency of chromium in a relative absence of blood insulin concentration. Three weeks of the treatment with CRC454 and CrP resulted in a 38% and 11% reduction of blood glucose levels, respectively. Body weight gains were equally improved by both treatments. Blood levels of CK, ALT and AST were significantly reduced by CRC454 and CrP. These results might suggest that any hypoglycemic effect of trivalent chromium under insulin-deficient conditions could be largely dependent upon the type of chromium agent and associated characteristics such as solubility and bioavalibility. In contrast, improvement of body weight gains and blood levels of CK, AST and ALT seems to be less dependent on the type of chromium compound under these experimental conditions. In conclusion, CRC454 showed significant reduction of hyperglycemia under insulin-deficient conditions.
authors.affiliation: Department of General Pathology, Clinic of Pediatrics, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland. machalin@sci.pam.szczecin.pl
authors.forename: Bogusław
authors.initials: B
authors.lastname: Machaliński
authors.forename: Mieczysław
authors.initials: M
authors.lastname: Walczak
authors.forename: Anhelli
authors.initials: A
authors.lastname: Syrenicz
authors.forename: Anna
authors.initials: A
authors.lastname: Machalińska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Grymuła
authors.forename: Iwona
authors.initials: I
authors.lastname: Stecewicz
authors.forename: Barbara
authors.initials: B
authors.lastname: Wiszniewska
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Dabkowska
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D002460:Cell Line; D002857:Chromium / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D066298:In Vitro Techniques; D007328:Insulin / Q000172:deficiency*; D008297:Male; D010848:Picolinic Acids / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007328:Insulin; D010848:Picolinic Acids; D002857:Chromium; D013311:Streptozocin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003402:Creatine Kinase; C030614:picolinic acid